CBS and Down syndrome: Before the role of CBS/H2S in cancer biology had emerged, and before the re-merging role of CBS/H2S in Down syndrome (see Section 2), there was no pharmacological reason to inhibit CBS (only to activate or reactivate it, for the treatment of homocystinuria, see above).